Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups

被引:3
|
作者
Fukuda, Tatsuya [1 ,2 ,3 ]
Okamoto, Takahiro [1 ]
Fukaishi, Takahiro [4 ]
Kawakami, Akio [5 ]
Tanaka, Makoto [4 ]
Yamada, Tetsuya [3 ]
Monzen, Koshiro [5 ]
机构
[1] Mirraza Shinjuku Tsurukame Clin, Tokyo, Japan
[2] Tokyo Metropolitan Okubo Hosp, Dept Endocrinol & Metab, Tokyo, Japan
[3] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Mol Endocrinol & Metab, Tokyo, Japan
[4] Koganei Tsurukame Clin, Tokyo, Japan
[5] Shinjuku Tsurukame Clin, Tokyo, Japan
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词
metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); metabolic and alcohol related/associated liver disease (MetALD); alcohol consumption; weight loss; INDEX; ASIA;
D O I
10.3389/fendo.2024.1392280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The incidence of steatotic liver disease has increased in recent years. Thus, steatotic liver disease is a major public health issue in Japan. This study investigated the association between weight reduction and the remission of metabolic dysfunction-associated steatotic liver disease (MASLD)/Metabolic and alcohol related/associated liver disease (MetALD) in Japanese individuals undergoing health checkups.Methods This retrospective observational study included 8,707 Japanese patients with MASLD/MetALD who underwent health checkups from May 2015 to March 2023. The participants were monitored for its remission at their subsequent visit. MASLD was diagnosed on abdominal ultrasonography and based on the presence of at least one of five metabolic abnormalities. The impact of body mass index (BMI) reduction on MASLD/MetALD remission was assessed via logistic regression analysis and using receiver operating characteristic curves.Results Logistic regression analysis revealed that weight loss was significantly associated with MASLD/MetALD remission. Other factors including exercise habits and reduced alcohol consumption were significant predictors of MASLD/MetALD remission in the overall cohort and in male patients. The optimal BMI reduction cutoff values for MASLD/MetALD remission were 0.9 kg/m2 and 4.0% decrease in the overall cohort, 0.85 kg/m2 and 3.9% decrease in males, and 1.2 kg/m2 and 4.5% decrease in females. In participants with a BMI of 23 kg/m2, the cutoff values were 0.75 kg/m2 and 2.7% BMI reduction.Discussion Weight reduction plays an important role in both MASLD and MetALD remission among Japanese individuals. That is, targeting specific BMI reduction is effective. This underscores the importance of targeted weight management strategies in preventing and managing MASLD/MetALD in the Japanese population.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups
    Fukuda, Tatsuya
    Akihisa, Taro
    Okamoto, Takahiro
    Fukaishi, Takahiro
    Kawakami, Akio
    Tanaka, Makoto
    Yamada, Tetsuya
    Monzen, Koshiro
    ENDOCRINE JOURNAL, 2025,
  • [2] Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction-associated steatotic liver disease
    Kehar, Mohit
    Ibrahim, Samar H.
    Ramirez, Charina M.
    Amin, Saista Asif
    Diamond, Tamir
    Mohammad, Saeed
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024, 79 (03) : 661 - 666
  • [3] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [4] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [5] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [6] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [7] Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study
    Peng, Yu
    Wang, Peng
    Liu, Fubin
    Wang, Xixuan
    Si, Changyu
    Gong, Jianxiao
    Zhou, Huijun
    Gu, Jiale
    Qin, Ailing
    Song, Weijie
    Song, Fangfang
    DIABETES OBESITY & METABOLISM, 2025, 27 (04) : 1940 - 1949
  • [8] Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients
    Babu, Ambrin Farizah
    Palomurto, Saana
    Karja, Vesa
    Kakela, Pirjo
    Lehtonen, Marko
    Hanhineva, Kati
    Pihlajamaki, Jussi
    Mannisto, Ville
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (12) : 2103 - 2110
  • [9] Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
    Portincasa, Piero
    Baffy, Gyorgy
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 35 - 39
  • [10] Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease
    Matteo, Maria Valeria
    Gualtieri, Loredana
    Bove, Vincenzo
    Palumbo, Giulia
    Pontecorvi, Valerio
    De Siena, Martina
    Barbaro, Federico
    Spada, Cristiano
    Boskoski, Ivo
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (08) : 397 - 405